Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its Appendix 4D financial report for the half year ending 31st December 2018.

Highlights for the period include:

- APVMA approval and product application of Detach

- Steven Lydeamore appointed CEO

- Product Development Advisory Board established

- Progression of GaRP dietary supplement development program

To view the full report, please visit:
http://abnnewswire.net/lnk/V5527M9X


About Anatara Lifesciences Limited

Anatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

    

Contact

General inquiries
Steven Lydeamore
CEO
Anatara Lifesciences
T: +61-438-027-172
E: slydeamore@anatara.com

Media inquiries:
Jane Lowe
Managing Director
IR Department
T: +61-411-117-774
E: jane.lowe@irdepartment.com.au



Link: Half Yearly Report and Accounts


Related Companies

Anatara Lifesciences Limited


Related Industry Topics: